Ann Arbor-area startup Gemphire Therapeutics just raised $2.7 million, according to a regulatory filing, for its drug that treats homozygous familial hypercholesterolemia. The drug candidate – called gemcabene – is being licensed from Pfizer, according to a December profile from Crain’s Detroit Business. The startup’s led by Mina Sooch, formerly CEO of Michigan’s ProNAi Therapeutics, which raised […]
Cancer drug developer ProNAi Therapeutics, which developed a nucleic acid-based DNA-interference technology to cause cancer cell death, has added nine new investors in an oversubscribed Series D round. The latest fundraise will help support Phase 2 clinical trials for its recurrent non-Hodgkin lymphoma treatment, follicular lymphoma, Richter’s transformation and large B-cell lymphoma, according to a […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A novel targeted cancer therapy may have a place in the multibillion-dollar cancer therapeutics market if it delivers positive results in an ongoing phase 1 clinical trial and attracts enough investor interest. Using nucleic acid-based DNA-interference technology, ProNAi Therapeutics has created a class of therapies to treat cancer and other complex genetic diseases. Its most […]
ProNAi uses gene silencing focused on DNA to attack a gene that helps tumor cells survive. In September the company launched a Phase I study on its treatment PNT2258, which will run through next year. The funding is likely to pay for this trial and others. ProNAi Chief Operating Officer Robert Forgey said in September the company had raised nearly $1 million to pay for the trial.
ProNAi Therapeutics in Kalamazoo, Michigan, says it's started to treat cancer patients with its first experimental DNA interference drug, which is made to silence the disease at the DNA level, according to Xconomy Detroit.